To the Editor Several recent meta-analyses of randomized clinical trials report contrasting results in regards to the protective effect of dietary supplementation with ω-3 polyunsaturated fatty acids (PUFAs) on cardiovascular disease risk. Based on these data, the American Heart Association recently modulated their suggestion on ω-3 PUFA supplementation, concluding it has potential usefulness in secondary prevention patients.1 In their meta-analysis carried out on 77 917 high-risk individuals participating in 10 trials, Aung et al2 further contrast the American Heart Association statement by demonstrating that ω-3 PUFAs supplementation was not associated with reduction in the risk of any vascular outcome.
Cicero AFG, Fogacci F, Borghi C. Questioning the Associations of ω-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. JAMA Cardiol. 2018;3(8):780–781. doi:10.1001/jamacardio.2018.1306
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: